Genmab Executes Share Buy-back Transactions in May 2025

Genmab ( (GMAB) ) has issued an announcement.

On May 26, 2025, Genmab A/S announced the execution of transactions related to its share buy-back program, initiated on March 25, 2025. The program aims to repurchase up to 2.2 million shares to reduce capital and fulfill commitments under the Restricted Stock Unit program, with completion expected by July 10, 2025. Between May 19 and May 23, 2025, Genmab repurchased 95,961 shares, bringing the total under the program to 2,079,611 shares. Following these transactions, Genmab holds 2,531,338 treasury shares, representing 3.95% of the total share capital and voting rights.

The most recent analyst rating on (GMAB) stock is a Hold with a $31.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.

Spark’s Take on GMAB Stock

According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.

Genmab exhibits strong financial performance with consistent profitability and low leverage. The company’s robust pipeline and strategic investments support future growth. However, technical analysis indicates neutral momentum, and dependency on key products introduces some risk.

To see Spark’s full report on GMAB stock, click here.

More about Genmab

Genmab is an international biotechnology company focused on developing innovative and differentiated antibody therapeutics. Established in 1999 and headquartered in Copenhagen, Denmark, the company has a significant presence in North America, Europe, and Asia Pacific. Genmab’s proprietary pipeline includes bispecific T-cell engagers, antibody-drug conjugates, and next-generation immune checkpoint modulators, aiming to transform the lives of people with cancer and other serious diseases by 2030.

Average Trading Volume: 1,540,379

Technical Sentiment Signal: Sell

Current Market Cap: $12.78B

For an in-depth examination of GMAB stock, go to TipRanks’ Stock Analysis page.